Search

Now showing items 1-10 of 21

Cabozantinib versus everolimus in patients with advanced renal cell carcinoma: Results of the randomized phase 3 METEOR trial

Choueiri, T; Escudier, B; Powles, T; Mainwaring, P; Rini, B; Donskov, F; Hammers, H; Hutson, T; Roth, B; Peltola, K;... (2015-09)

Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma

Kurtoglu, M; Davarpanah, NN; Qin, R; Powles, T; Rosenberg, JE; Apolo, AB (2015-10)

Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210)

Rosenberg, J; Petrylak, D; Abidoye, O; Van der Heijden, MS; Hofman-Censits, J; Necchi, A; O'Donnell, PH; Balmanoukian, A; Loriot, Y; Retz, M;... (2015-09)

A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer

Berlato, C; Khan, MN; Schioppa, T; Thompson, R; Maniati, E; Montfort, A; Jangani, M; Canosa, M; Kulbe, H; Hagemann, UB;... (2017-03-01)

HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer

Xu, C-F; Johnson, T; Wang, X; Carpenter, C; Graves, AP; Warren, L; Xue, Z; King, KS; Fraser, DJ; Stinnett, S;... (2016-03-15)

Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer

Powles, T; Sarwar, N; Stockdale, A; Sarker, S-J; Boleti, E; Protheroe, A; Jones, R; Chowdhury, S; Peters, J; Oades, G;... (2016-10-01)

Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project(aEuro)

Kramar, A; Negrier, S; Sylvester, R; Joniau, S; Mulders, P; Powles, T; Bex, A; Bonnetain, F; Bossi, A; Bracarda, S;... (2015-12)

Patterns and potential benefit of adjuvant chemotherapy for residual muscle invasive disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC)

Harshman, L; Werner, L; Wong, YN; Yu, E; Alva, A; Crabb, S; Powles, T; Rosenberg, J; Baniel, J; Vaishampayan, U;... (2015-09)

Development and validation of an ultra-high performance LC-MS/MS assay for intracellular SN-38 in human solid tumour cell lines: Comparison with a validated HPLC-fluorescence method

Ghazaly, E; Perry, J; Kitromilidou, C; Powles, T; Joel, S (2014-10-15)

SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair

Kanu, N; Groenroos, E; Martinez, P; Burrell, RA; Goh, XY; Bartkova, J; Maya-Mendoza, A; Mistrik, M; Rowan, AJ; Patel, H;... (2015-11-12)